Loading…
← CockpitCompetitor Analysis › 301206.SZ Shandong Sanyuan Biotechnology Co. Ltd. Class AOpen in the cockpit ↗

Shandong Sanyuan Biotechnology Co. Ltd. Class A301206.SZCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Major Diversified
Momentum neutral 59
Mkt cap
$644M
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$4.73M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.4 pp
WACC 7.9%
Hurdle
n/a
no reverse DCF
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥21.38
1D-1.8%
1W-3.4%
1M-12.9%
3M-10.8%
6M-20.7%
YTD-18.7%
1Y-21.7%
ATR %2.9%
52w lowhigh29.9% off high

What Shandong Sanyuan Biotechnology does

Employees: 441

Shandong Sanyuan Biotechnology at a glance

Size Shandong Sanyuan Biotechnology (301206.SZ) is a China Materials company (Chemicals: Major Diversified) with a market value of $644M, the 3083rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.38 on 18 Nov 2026.

Performance Over six months the shares fell 20.7%, against -27.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 15.4% over the last twelve months (peer median +6.3%); the operating margin is 4.2% (peer median 6.4%).

Valuation It trades at 3.7× enterprise value to sales against a peer median of 3.3× (10th most expensive of 21).

Capital Return on invested capital runs 5.4 points below its cost of capital (7.9% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026301206.SZ 80Peer median 72
Six months, rebased to 100: Shandong Sanyuan Biotechnology against the median of its 20 peers (local-currency closes).

Shandong Sanyuan Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥778MCN¥649MCN¥713MCN¥500MCN¥675M
Revenue growth—-9%+43%-26%—
Gross profitCN¥166MCN¥94.8MCN¥73.3MCN¥6.14MCN¥85.9M
EBITDAn/aCN¥102MCN¥73.7MCN¥176,270CN¥69.3M
Net incomeCN¥77.7MCN¥91.4MCN¥105MCN¥56.0MCN¥164M
Free cash flow-CN¥3.24MCN¥119M-CN¥121M-CN¥65.7M-CN¥158M
Capital expenditureCN¥163MCN¥199MCN¥142MCN¥123MCN¥243M
Total debtCN¥14.6MCN¥10.8MCN¥94.8MCN¥165MCN¥102M

Quarterly statements and history in the cockpit →

Shandong Sanyuan Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%0006350022743000826001653005306882376032853001215234688750603004300801ACI30053760536641894975603351300839688267301206.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Sanyuan Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%5×10×0006350022743000826001653005306882376032853001215234688750603004300801ACI30053760536641894975603351300839688267301206.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Sanyuan Biotechnology is the large dot.

Shandong Sanyuan Biotechnology competitors and peer comparison

How Shandong Sanyuan Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Sanyuan Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure301206.SZPeer medianRank in peer set
1-month return-12.9%-9.9%8th lowest of 21
6-month return-20.7%-27.3%9th highest of 21
Distance from 52-week high-29.9%-40.7%6th highest of 21
Revenue growth (TTM)+15.4%+6.3%3rd highest of 21
Operating margin4.2%6.4%8th lowest of 21
EV / Sales3.7×3.3×10th most expensive of 21
ROIC minus cost of capital-5.4 pp-1.8 pp8th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shandong Sanyuan Biotechnology 301206.SZChina$644M-21%+15%4%3.7×n/an/a
Ningxia Yinglite Chemicals 000635.SZChina$650M+35%-14%-48%3.2×n/an/a
Jiansu Huachang Chemical 002274.SZChina$663M-25%+9%-3%0.7×23.2%+1.3%
Liaoning Oxiranchem,Inc 300082.SZChina$673M-45%+4%0%1.3×n/an/a
Ningxia Zhongke Biotechnology 600165.SSChina$601M-17%+8%-73%7.7×n/an/a
Hunan Lead Power Technology 300530.SZChina$691M+12%+16%-61%31.9×n/an/a
Hubei Chaozhuo Aviation Technology 688237.SSChina$697M-5%-1%1%10.8×43.1%+26.0%
Shandong Jianbang New Material 603285.SSChina$594M-50%+8%22%4.8×n/an/a
Shandong Yanggu Huatai Chemical 300121.SZChina$703M-16%+11%8%1.2×4.7%+12.1%
Daxin Materials 5234.TWTaiwan$705M-39%+12%20%4.5×15.9%+1.5%
Hunan Xiangtou Goldsky Titanium Industry Technology 688750.SSChina$585M-29%+4%6%6.2×28.9%-4.3%
Zhejiang Dragon Technology 603004.SSChina$582M-22%-11%16%4.2×15.8%+1.7%
Shandong Taihe Technologies 300801.SZChina$582M-42%-2%7%1.2×5.2%+12.9%
Archean Chemical Industries ACI.NSIndia$576M-19%+6%12%5.0×n/an/a
Jiangsu Kuangshun Photosensitivity New Material Stock 300537.SZChina$568M-33%+15%6%6.5×41.7%-8.5%
Jiangxi Hungpai New Material 605366.SSChina$736M-46%+9%-11%3.2×n/an/a
KH Neochem 4189.TJapan$738M+20%-6%12%1.2×-5.0%+8.3%
JCU 4975.TJapan$744M-34%+5%39%3.0×5.5%+7.0%
Nanjing Well Pharmaceutical 603351.SSChina$550M-2%+7%13%2.7×3.0%+12.7%
Ningbo Bohui Chemical Technology 300839.SZChina$533M-35%+42%4%1.0×1.2%+23.1%
China Catalyst 688267.SSChina$532M-38%-3%18%3.4×n/an/a

Questions

Which companies are Shandong Sanyuan Biotechnology's closest peers?
The cockpit's peer set: Ningxia Yinglite Chemicals (000635.SZ), Jiansu Huachang Chemical (002274.SZ), Liaoning Oxiranchem,Inc (300082.SZ), Ningxia Zhongke Biotechnology (600165.SS), Hunan Lead Power Technology (300530.SZ), Hubei Chaozhuo Aviation Technology (688237.SS), Shandong Jianbang New Material (603285.SS), Shandong Yanggu Huatai Chemical (300121.SZ).
Is Shandong Sanyuan Biotechnology expensive compared with its peers?
On ev / sales it trades at 3.7× against a peer median of 3.3×, 10th most expensive of 21 in its peer set.
How has Shandong Sanyuan Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -20.7% against -27.3% for the median peer; over one year -21.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.